NCT04550234 - A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 13, 2021

Primary Completion Date

July 15, 2021

Study Completion Date

July 15, 2021

Conditions

Chronic Kidney Disease

Interventions

DRUG

Verinurad prolonged release HPMC capsule

Randomized subjects will receive oral dose of verinurad HPMC capsule.

DRUG

Allopurinol Tablet

Randomized subjects will receive oral dose of allopurinol tablet.

DRUG

Verinurad/Allopurinol FDC Capsule

Randomized subjects will receive oral dose of Verinurad/Allopurinol FDC capsule.

DRUG

Verinurad prolonged release gelatin Capsule

Randomized subjects will receive oral dose of Verinurad gelatin capsule.

Trial Locations (1)

Research Site, Berlin